Perioperative Monitoring of Serum RalA Autoantibodies in the Patients Treated with Radical Surgery
| Project/Area Number |
26462029
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Toho University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
島田 英昭 東邦大学, 医学部, 教授 (20292691)
牛込 充則 東邦大学, 医学部, 助教 (90408849)
鈴木 孝之 東邦大学, 医学部, 助教 (10385768)
|
|---|
| Project Period (FY) |
2014-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | RalA / p53 / 大腸癌 / 血清抗体 / 腫瘍マーカー / SEREX / CEA |
|---|
| Outline of Final Research Achievements |
【Background and Purpose】Anti-RalA-IgG antibodies appear in the serum of cancer patients from the early stages of carcinogenesis. This serum RalA-IgG antibody is developed as a novel biomarker.【Patients and Methods】Preoperative serum and resected specimen were analyzed in 289 patients with colorectal cancer.【Results】 The positive rate of serum RalA-IgG antibody was 14%. The positive rate increased as the stage progression, but the relevance to the prognosis was unclear. Serum antibodies were not correlated with CEA, CA19-9 nor p53 antibodies. Immunostaining of tissues showed a moderate correlation with serum antibody titer.【Conclusion】Serum RalA antibody in the patients with colorectal cancer seems to be useful.
|
| Academic Significance and Societal Importance of the Research Achievements |
既存の腫瘍マーカーであるCEA, CA19-9, p53抗体いずれの陰性である約４０％の大腸癌症例で一定の陽性率となることから、CEA,CA19-9,p53抗体のいずれとも独立している血清RALA抗体検査の意義がある。血液検査による大腸癌のスクリーニングに寄与するものと思われる。
|
Report
(6 results)
Research Products
(16 results)
-
-
-
-
[Journal Article] NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers2015
Author(s)
Oshima Y, Shimada H, Yajima S, Nanami T, Matsushita K, Nomura F, Kainuma O, Takiguchi N, Soda H, Ueda T, Iizasa T, Yamamoto N, Yamamoto H, Nagata M, Yokoi S, Tagawa M, Ohtsuka S, Kuwajima A, Murakami A, Kaneko H
-
Journal Title
J Gastroenterol
Volume: Epub ahead of print
Issue: 1
Pages: 30-34
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
[Presentation] 大腸癌術前後の血清p53検査の意義.2016
Author(s)
鈴木孝之, 船橋公彦, 小池淳一, 大久保和範, 三浦康之, 吉田公彦, 甲田貴丸, 金子奉暁, 牛込充則, 塩川洋之, 栗原聰元, 島田英昭, 金子弘真
Organizer
第71回日本大腸肛門病学会学術集会
Place of Presentation
三重県営サンアリーナ（三重県伊勢市）
Year and Date
2016-11-19
Related Report
-
[Presentation] 大腸癌血清p53 抗体値と補助化学療法の関連性についての検討.2016
Author(s)
牛込充則, 小池淳一, 鈴木孝之, 島田英昭, 甲田貴丸, 吉田公彦, 岡田 嶺, 金子奉暁, 栗原聰元, 鏡 哲, 吉野 翔, 船橋公彦, 塩川洋之, 長嶋康雄, 澤口悠子,金子弘真
Organizer
第116回日本外科学会定期学術集会
Place of Presentation
リーガロイヤルホテル大阪（大阪府大阪市）
Year and Date
2016-04-14
Related Report
-
-
-
-
-
-
